D2
12 drugs CNS
3
approved indications
12
Approved Drugs
9
Companies
7
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 12 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (7 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Johnson & Johnson 4 drugs
STERISCIENCE 1 drug
CHEPLAPHARM ARZNEIMITTEL GMBH 1 drug
By Therapeutic Area
CNS 12 drugs
Drugs by Company PRO
Johnson & Johnson 4 drugs
STERISCIENCE 1 drug
CHEPLAPHARM ARZNEIMITTEL GMBH 1 drug
INTRA-CELLULAR 1 drug
SHANDONG LUYE 1 drug
VANDA PHARMS INC 1 drug
Dr. Reddy's 1 drug
LUYE INNOMIND PHARMA 1 drug
CHEPLAPHARM 1 drug
By Therapeutic Area
CNS 12 drugs
ZIPRASIDONE MESYLATE, SEROQUEL XR, CAPLYTA, RYKINDO +8 more
Indications Treated
SchizophreniaBipolar I DisorderBipolar DisorderAgitationMajor Depressive DisorderSchizoaffective DisorderAutistic Disorder
All Drugs Targeting D2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| ZIPRASIDONE MESYLATE | STERISCIENCE | 2019 | 3 | CNS |
| SEROQUEL XR | CHEPLAPHARM ARZNEIMITTEL GMBH | 2007 | 3 | CNS |
| CAPLYTA | INTRA-CELLULAR | 2019 | 3 | CNS |
| RYKINDO | SHANDONG LUYE | 2023 | 3 | CNS |
| FANAPT | VANDA PHARMS INC | 2009 | 2 | CNS |
| RISPERDAL | Johnson & Johnson | 1993 | 2 | CNS |
| INVEGA SUSTENNA | Johnson & Johnson | 2009 | 2 | CNS |
| ZIPRASIDONE HYDROCHLORIDE | Dr. Reddy's | 2012 | 2 | CNS |
| ERZOFRI | LUYE INNOMIND PHARMA | 2024 | 2 | CNS |
| SEROQUEL | CHEPLAPHARM | 1997 | 2 | CNS |
| RISPERDAL CONSTA | Johnson & Johnson | 2003 | 2 | CNS |
| INVEGA TRINZA | Johnson & Johnson | 2015 | 1 | CNS |